Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Infection with Clostridium difficile is currently the leading cause of infectious diarrhea in hospitalized patients, and recent surveillance data indicate that C. difficile has surpassed methicillin-resistant Staphylococcus aureus as the number one cause of hospital-acquired infections in some areas of the USA. In addition, concern over C. difficile has increased over the past decade due to the appearance of new hypervirulent strains. Metronidazole and vancomycin have remained the treatments of choice for initial therapy of primary infection with C. difficile for the past 25 years, but the persistence of spores leads to a recurrence of infection in an estimated 20-25% of patients. Patients who have one recurrent episode have up to a 65% chance of having additional recurrence. While the judicious use of antimicrobials in accordance with antibiotic stewardship guidelines remains the most effective method for the control of C. difficile, the high recurrence rate, increasing incidence, and changing epidemiology of C. difficile has led to an increased interest in the study of alternative strategies for the prevention and treatment of C. difficile disease. These alternative strategies attempt to eliminate C. difficile spores, replenish the normal gut flora, reduce the C. difficile toxin load in the bowel, or bolster the patient's own immune response to the C. difficile toxins. To evaluate the available evidence on these alternative strategies, we conducted a literature search of MEDLINE (1966-March 2011) and International Pharmaceutical Abstracts (1970-March 2011). Available citations from these articles were also utilized. The aim of this review is to summarize the available evidence for alternative treatment strategies for C. difficile disease and to make recommendations for their place in therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872
Khoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c87e02 · Cited by 649
Hickson, M., D'Souza, A. L., Muthu, N., Rogers, T. R., Want, S., Rajkumar, C., & Bulpitt, C. J. (2007) · BMJ · doi:10.1136/bmj.39231.599815.55 · Cited by 599
Bacteriotherapy Using Fecal Flora: Toying With Human Motions
Borody, T. J., Warren, E. F., Leis, S. M., Surace, R., Ashman, O., & Siarakas, S. (2004) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000128988.13808.dc · Cited by 283
Regulatory Oversight and Safety of Probiotic Use
Venugopalan, V., Shriner, K. A., & Wong-Beringer, A. (2010) · Emerging Infectious Diseases · doi:10.3201/eid1611.100574 · Cited by 216
Cited by
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
Cammarota, G., Masucci, L., Ianiro, G., Bibbò, S., Dinoi, G., Costamagna, G., Sanguinetti, M., & Gasbarrini, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13144 · Cited by 558
Diagnosis and Treatment of Clostridium difficile in Adults: A Systematic Review
Bagdasarian, N., Rao, K., & Malani, P. N. (2015) · JAMA · doi:10.1001/jama.2014.17103 · Cited by 451
Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options
Lo Vecchio, A., & Zacur, G. M. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834bc9a9 · Cited by 183
Metadata
- Authors
- Musgrave, C. R., Bookstaver, P. B., Sutton, S. S., & Miller, A. D.
- Venue
- International Journal of Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 15
- Issue
- 7
- Pages
- e438-e448
- ISSN
- 1201-9712 (ISSN-L)
- OpenAlex
- W1998361279
- Cited by
- 50
- References
- 5
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.